gi-hepatology surgery
Pancreatic Fistula Risk Score (FRS) after Pancreatoduodenectomy
Validated risk score for clinically relevant postoperative pancreatic fistula (CR-POPF) after pancreatoduodenectomy (Whipple procedure). Based on gland texture, pathology, pancreatic duct diameter, and intraoperative blood loss. Score 0-10; score 7-10 = high risk. From Callery et al. 2013 and modified Fistula Risk Score (a-FRS) by Mungroop et al. 2019.
References
- Callery MP et al. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg. 2013;216(1):1-14.
- Mungroop TH et al. Alternative Fistula Risk Score (a-FRS) for Pancreatoduodenectomy. Ann Surg. 2019;269(5):937-943.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Octreotide (Surgical — Fistula/Carcinoid) · Somatostatin Analogue
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Octreotide · Gastrointestinal Emergency
- Octreotide · Somatostatin Analogue
- Orlistat · Pancreatic lipase inhibitor
- Pancreatin (Pancreatic Enzyme Replacement Therapy — PERT) · Pancreatic Enzyme Supplement
Pathways
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.